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Abstract
Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and
the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of
choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth
factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF’s
neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological
neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and
prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse
model of AMD.Methods and Findings: Lodamin, a polymeric formulation of TNP-470, is a potent broad-spectrum
antiangiogenic drug. Lodamin significantly reduced key processes involved in AMD progression as demonstrated in mice
and rats. Its suppressive effects on angiogenesis, vascular leakage and inflammation were studied in a wide array of assays
including; a Matrigel, delayed-type hypersensitivity (DTH), Miles assay, laser-induced CNV and corneal micropocket assay.
Lodamin significantly suppressed the secretion of various pro-inflammatory cytokines in the CNV lesion including monocyte
chemotactic protein-1 (MCP-1/Ccl2). Importantly, Lodamin was found to regress established CNV lesions, unlike soluble fms-
like tyrosine kinase-1 (sFlk-1). The drug was found to be safe in mice and have little toxicity as demonstrated by
electroretinography (ERG) assessing retinal and by histology.
Conclusions: Lodamin, a polymer formulation of TNP-470, was identified as a first in its class, broad-spectrum
antiangiogenic drug that can be administered orally or locally to treat corneal and retinal neovascularization. Several unique
properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum
antiangiogenic drugs are promising agents for AMD treatment and prevention.
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Introduction
Ocular neovascular-related diseases are associated with vision
impairment or vision loss in millions worldwide. The growth of
abnormal, leaky blood vessels is a prominent component of several
debilitating eye diseases including AMD, proliferative diabetic
retinopathy (PDR), and retinopathy of prematurity (ROP).
Therefore antiangiogenic strategies could be particularly beneficial
in preventing and treating the progression of these diseases.
Corneal neovascularization is often the result of inflammation,
chemical burns, and conditions related to hypoxia[1,2]. These
conditions are currently treated by indirect angiogenesis inhibitors
such as steroids and immunosuppressants[1]. Inhibition of retinal
nonvascular disease, such as AMD, has been focused on targeting
the angiogenic factor VEGF and these therapies are the current
gold standard in the treatment of neovascular AMD.
The most prominent class of VEGF blocking therapy is
represented by ranibizumab and bevacizumab. These molecules
are derived from a humanized anti-VEGF antibody which has the
ability to reduce retinal edema in AMD[3]. While clinical trials
have shown a beneficial effect in 30–40% of treated patients[3,4],
in many cases these therapies become less effective over time[5].
VEGF blockade can halt angiogenesis and reduce vessel leakage,
but does not cause regression of existing vessels [6]. The effect of
VEGF traps is short lived and thus repeated intravitreal injections
every 4 weeks is required[4]. Moreover, it has been shown that
retinal pigment epithelium (RPE)-derived soluble VEGF has a role
in maintenance of the choriocapillaris[7] and that VEGF is
neuroprotective in the retina Thus chronic treatment with anti-
VEGF therapy may induce long term damage to the retina.
In recent years diverse cellular processes have been implicated
in the pathenogenesis of retinal diseases such as AMD or PDR.
These processes include oxidative stress, vascular permeability,
fibrosis, inflammation and impaired function of RPE[8]. Given the
multifactorial nature of neovascularization and the contribution of
the microenvironment, the search for more effective therapies to
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12515block CNV has shifted toward targeting multiple processes rather
than a single pathway[9]. In this study we investigated different
components involved in the pathology of AMD using distinct
assays for angiogenesis, inflammation and vascular permeability.
We investigated the progression of CNV in response to a broad
spectrum antiangiogenic drug that was found to directly inhibit
ocular neovascularization while also inhibiting inflammatory and
angiogenic signals. This type of therapy may offer an improvement
over current treatments and an alternative where existing
therapies fail.
Lodamin, monometoxy poly(etylen)glycol-poly(lactic acid) (mPEG-
PLA)-TNP-470, is water soluble and orally available antiangiogenic
drug. Lodamin has reduced TNP-470-releated cerebellar side
effects and has been shown to have potent anti-cancer activity and
inhibit liver metastases in mice. [10] In this study we investigated its
efficacy in ophthalmology and studied the drug’s effect on key
processes in AMD.
Using the CNV model in mice and rats, our findings
demonstrated the potency of Lodamin as a broad-spectrum
antiangiogenic ophthalmic drug in inhibiting neovascularization,
edema and inflammation by targeting numerous molecular
pathways in addition to VEGF. Importantly, we found the
antiangiogenic activity of Lodamin to induce the regression of
established CNV lesions unlike VEGF trap (Flk-1) that solely
inhibited CNV growth. Additionally, the broad activity of
Lodamin was found to cause no adverse effects in retinal function
as demonstrated with ERG. Its safety and unique activity place it
as a leading candidate for treating corneal and retinal neovascular
diseases.
Results
Lodamin inhibits angiogenesis and macrophage
recruitment in vivo
To investigate Lodamin’s effect on angiogenesis and macro-
phage recruitment, a quantitative mouse Matrigel angiogenesis
assay was performed. Vasculature in Matrigel plugs was visually
assessed at day 7 post Matrigel injection (Figure. 1 A) and by
immunohistochemical staining of blood vessels using anti-CD31
antibodies (Figure 1A). Immunohistology revealed that Lodamin
dramatically reduced angiogenesis compared with untreated mice
which presented numerous large blood vessels with open lumen
structures (n=5). Infiltrated endothelial cells and macrophages in
Matrigel matrices were quantified in a single-cell suspension by
fluorescence-activated cell sorting (FACS) (Figure 1B, Figure S1A).
After 7 days of oral Lodamin treatment, significant reductions of
infiltrating endothelial cells and macrophages were seen in the
Lodamin group compared to vehicle treated mice (endothelial
cells: 0.1160.06% versus 0.4960.11%; macrophages: 3067%
versus 4369% in Lodamin and control groups, respectively).
Systemic and local Lodamin treatment inhibit corneal
neovascularization
Antiangiogenic activity of Lodamin following topical or systemic
administration was evaluated in the mouse corneal micropocket
assay using bFGF-induced neovascularization. Mice were treated
with Lodamin by oral administration (30 mg/kg/d q.d for 5 days),
subconjunctional injection (30 mg/ml q.d for 5 days) or topical eye
drops (30 mg/ml q.d for 5 days). These treatments resulted in a
37%, 38% or 30% reduction in corneal vessel area from control
respectively. Figure 1C and D shows representative images taken
from the designated groups and the quantification of vessel area
(Figure 1D).
Lodamin reduces Delayed-Type Hypersensitivity (DTH)
ear-swelling
The multifactorial effect of Lodamin treatment on angiogenesis,
inflammation, vascular hyperpermeability and edema was studied
in the DTH reaction. C57Bl/6J mice were sensitized with
oxazolone and then treated with Lodamin orally (15 mg/kg q.d.)
starting from 5 days post initial exposure to oxazolone. As early as
day 2 and up to day 12 (with the exceptions of days 4 and 5) a
significant reduction of ear erythema and swelling was registered
in Lodamin-treated mice compared with vehicle treated mice
(Figure 2). Hematoxillin and Eosin (H&E) staining of histological
ear sections (Figure 2C,a–f) confirmed markedly reduced swelling
and edema in treated mice compared to untreated mice. Unlike
the treated mice, control mice demonstrated thick epidermis with
extensive edema as illustrated by cell spongiosis, high cellularity
and infiltrating monocytes (Figure 2C). A chronic response
consisting of neutrophil accumulation and enhanced fibroblast
proliferation was also detected in the untreated tissues. In some
samples, acute inflammation associated with focal polynuclear cell
accumulations was found. Immunostaining of blood vessels with
anti-CD31 antibodies revealed significant reduction of angiogen-
esis by Lodamin (Figure 2C, g–h). By staining with CD45 and F4/
80, we also observed reduction of infiltrated leukocytes and
macrophages in Lodamin treated mouse ears (Figure S1B).
Oral or intravitreal treatment of Lodamin reduces CNV
progression
The effect of Lodamin on CNV progression in mice was
determined after oral or intravitreal administration. Oral Lodamin
was administered at multiple doses and durations: 15 mg/kg/day
(for 7 days and 14 days of treatment) and 30 mg/kg dose (7 days).
CNV lesions in choroidal flat-mounts were evaluated after lectin
staining for blood vessels with anti-CD31 antibody. CNV area was
significantly reduced by Lodamin in all treatment groups
(Figure 3A). Higher doses and longer treatment led to an
enhanced effect: 14 day treatment with 15 mg/kg q.d. gave
70.6% inhibition, while 7 day treatment at the same dose yielded
27.2% inhibition. Additionally, at 30 mg/kg/day dosing a more
dramatic inhibition was obtained (50.5%) after 7 days. Figure 3A
summarizes CNV area of all treatment groups. Representative
images of retinal flat-mounts stained for blood vessels are shown in
Figure 3B. H&E staining revealed that Lodamin substantially
reduced the formation of fibrovascular response from the choroid
which was induced in the spot rupture of Bruch’s membrane by
the photocoagulation laser (Figure 3C). Recruitment of macro-
phages into CNV lesions over time was evaluated by FACS in
single-cell suspensions originating from mouse retinal tissue.
Retinal infiltrated macrophages were reduced following Lodamin
treatment (30 mg/kg/day, oral) as shown by the control group
which had 2% and 3.6% infiltrating macrophages on day 3 and 7
respectively compared with Lodamin treated groups that showed
1.8% and 2.3% macrophages on days 3 and 7, respectively
(Figure 3D). When Lodamin was introduced by a single
intravitreal injection of 100 mg/eye or 300 mg/eye, 56% or 75%
suppression were obtained, respectively, after 14 days (Figure 4).
No significant difference was found when injecting PBS compared
to vehicle (data not shown). Figure 4B shows representative CNV
lesions from the different groups and their size measurements.
Lodamin regresses established CNV lesions whereas sFlk-
1 solely inhibits further growth
To determine whether therapies cause regression in CNV lesions
or merely inhibit their further growth, we compared the effects of
Ocular Neovascularization
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12515Figure 1. Lodamin inhibits angiogenesis and inflammation in Matrigel plugs and inhibits corneal neovascularization after local or
oral treatment. (A) Matrigel containing VEGF and bFGF was injected subcutaneously (s.c., n=5) to determine the effect of Lodamin on
angiogenesis and macrophage infiltration. Upper panel shows representative plugs removed from Lodamin treated or untreated mice (bar=1 cm).
Bottom panel shows vessel staining with anti-CD31 antibody (brown) and nuclei staining with Hematoxilin Gill’s (blue), bar=100mm; arrows point to
large vessel with open lumans (B) Quantification of infiltrating endothelial cell or macrophages in Matrigel plugs. Data are presented as percent of
specific cell population out of the total cell population (n=3–4, p,0.05). (C) Antiangiogenic activity of Lodamin following topical or systemic
administration was evaluated in the mouse corneal micropocket assay using bFGF-induced neovascularization. Quantification of vessel area (mm
2)i n
different corneal assays performed with Lodamin which were administered either orally (30 mg/kg q.d), by eye drops (30 mg/ml, q.d) or by
subconjunctival injections (30 mg/ml, q.d). Graphs indicate the significant inhibition of vessel formation after 5 days of treatment. Vessel area was
reduced by 38% after subconjunctival injection (P=0.0002), by 30% after eye drops treatment (P=0.003), and by 37% (P=0.04) after oral
administration. In each group n=10. (D) Representative images taken from the different groups at day 5; bFGF pellet is detected as a white spot in
the center of the cornea, blood vessels growing from limbal periphery are reduced in Lodamin treated group compared to controls. Vessel area in
mm
2 is calculated by the following formula: p6clock hours6vessel length (mm)60.2 mm.
doi:10.1371/journal.pone.0012515.g001
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mice. Seven days post laser induction, mice were injected
intravitreally with Lodamin (100 mg/eye), or with sFlk-1 (3 mg/
eye) or saline (as sham injection control). On day 14 post laser
induction(7daysposttreatment)the sizesofCNVinallmicegroups
were measured, and also compared to original size of the CNV in
mice 7 days post laser induction (untreated). The Lodamin treated
group was found to have CNV which were smaller by 65%
compared to the sham group on day 14 (7 days post treatment).
Importantly, when compared with the baseline size of CNV in
untreated mice at day 7, a 45% regression was detected. While sFlk-
treated group was found to have CNV which were smaller by 41%
compared to the sham group on day 14, no significant reduction
was found when compared to untreated mice at day 7, confirming
inhibition of CNV growth without regression (Figure 5).
Lodamin has minimal toxic effects on retinal function
To evaluate possible adverse side effects of Lodamin treatment,
retinal function was assessed by electroretinography (ERG). Normal
C57BL/6J mice were injected intravitreally with the highest dose
studied of Lodamin (300 mg; n=10) or vehicle (n=1 0 )a n dt e s t e d1 4
days after injection. Responses to a ,6.6 log unit range of intensities
of full-field flashes presented to the dark-adapted eye were recorded
(Figure 6A) as was the response to an 8 Hz flickering light presented
in the presence of an adapting background (Figure 6B). Rod
photoreceptor response sensitivity (Srod) and saturating amplitude
Figure 2. Lodamin inhibits angiogenesis, inflammation and edema in the DTH reaction. (A) Lodamin suppressed ear swelling in DTH
reactions elicited by oxazolone, photos of representative ears of Lodamin treated or untreated mice are circled. Bar=1 cm (B) Ear swelling is
represented as change in thickness (in mm) compared to original ear thickness. Mice treated with Lodamin (white squares) showed a significant
reduction in ear thickness compared to control mice (black squares). The differences were statistically significant from day 2 to day 12 post challenge,
excluding day 5 (P,0.05). Data are presented as an average 6SEM, n=5. (C) Immunohistological analysis of mouse ears post DTH reaction: H&E
staining (a–f) and specific staining of endothelial cell marker CD-31 (g–h). In H&H staining, control ears exhibited an excessive inflammation and
edema (a–d), including fibroblast proliferation (marked as F) and spongiosis pointed by arrows compared with Lodamin treated mice (e–f).
Bar=50mm.
doi:10.1371/journal.pone.0012515.g002
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sensitivity (kP2) and saturating amplitude (RmP2) were derived from
the ERG b- w a v e( F i g u r e6 C ) .T h es a t u r a t i n ge n e r g yi nt h eE R G
oscillatory potentials (Em), and the trough-to-peak amplitude of the
flicker response (R8) were also determined (Figure S2A, S2B). For
each of the six ERG parameters, in log scale, the mean and 5
th and
95
th prediction limits for normal were calculated and compared to
those of Lodamin-treated mice (Figure 4C); Nearly every observation
(56 of 60) in Lodamin-treated mice fell within the normal range. Only
RmP3 differed significantly (P=0.46) between groups, by ,0.15 log
unit. In histological examination no toxicity was observed in
histological H&E whole eye samples (Figure S2C).
Lodamin reduces pro-angiogenic and inflammatory
factors in CNV bearing mice
Levels of different pro-inflammatory and pro-angiogenic factors
were measured using specific antibody by enzyme-linked immuno-
sorbent assay (ELISA) or western blot analysis. Significant reductions
of MCP-1 and VEGF in retina-choroids tissues were found in
Lodamin treated mice by ELISA. MCP-1 was not detectable in naı ¨ve
mice but was found in high concentrations in CNV bearing mice
(48663 pg/mg in control CNV mice) and 61% lower level in
Lodamin treated mice (Figure 6D). Unlike MCP-1, VEGF baseline
levels in naı ¨v em o u s ee y e sw e r ea l m o s ta sh i g ha st h e s ei nC N V
bearingmice(313 pg/mg,320 pg/mg respectively). Lodamintreated
mice reduced VEGF levels to 24% below the baseline (243 pg/mg).
MCP-1 levels in primary RPE cultures were also measured by ELISA
and were found to be reduced by Lodamin in a dose dependant
manner after 24 h treatment (39%, 55%, 83% reduction was
obtained with 1, 10, 100 nM Lodamin, respectively). All ELISA data
were normalized to total protein in each sample (Figure 6D).
The levels of TNFa, a major inflammatory cytokine, were
higher in choroid than in retina and were reduced in the choroid
by Lodamin (Figure 6E). NF-kB, a pro-inflammatory transcription
Figure 3. Oral treatment of Lodamin reduces CNV progression. (A) CNV lesion size of Lodamin-treated mice compared to controls. A dose of
15 mg/kg/day was administered for 7 or 14 days and a dose of 30 mg/kg/day was administered for 7 days. CNV lesions in choroidal flat mounts were
evaluated after staining of blood vessels using isolectin-IB4 conjugated with Alexa Fluor 488. Data are presented as percent of blood vessel area in
choroidal flat mounts (pixels) of treatment per controls. Data are expressed as mean 6 SEM, (U-test, * P,0.05, ** P,0.005, n=10). (B) Representative
images of CNV lesions stained with a lectin-FITC in flat mount of mouse choroids. Bar=20 mm. (C) H&E stained histological side sections of CNV site in
Lodamin treated or untreated mice. Substantial differences in fibrous tissues thickness and choroidal vessel invasion to CNV site are detected,
Bars=50 mm( D) FACS analysis of single-cell suspension originated from retinas after 3 and 7 days of oral Lodamin treatment. Quantification of
macrophage infiltration in mouse retinas originated from Lodamin treated (30 mg/kg, daily, oral) or mice which were treated with equivalent dose of
vehicle. Macrophage population was detected as a double positive CD45+ and F4/80+ staining.
doi:10.1371/journal.pone.0012515.g003
Ocular Neovascularization
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and was also reduced in the choroid by Lodamin. MMP-2 and 9
activity in CNV lesions was determined following oral Lodamin
treatment (30 mg/kg q.d for 7 days) using zymogram (Figure 6F).
The enzymatic activity was accelerated in tissues with CNV
compare to naı ¨ve mouse tissues, while both MMP-2 and 9
activities were reduced by Lodamin to the levels of naı ¨ve mice.
Lodamin reduces MCP-1 and VEGF induced vessel
permeability
We further investigated MCP-1’s role on vessel permeability and
Lodamin’s ability to antagonize this effect. In the modified in vivo Miles
assay, MCP-1 enhanced vessel permeability in concentrations of 10,
60, 100, 250 pg/ml (n=15). Representative mouse skin patches
showing Evan’s blue leakage in MCP-1 injection spots are presented in
Figure S3. The effect of Lodamin on MCP-1-induced vessel leakage
was measured after 5 days of oral pretreatment with 30 mg/kg/day in
C57Bl/6J mice (Figure 7A). An 87% reduction in vessel permeability
was obtained. Similarly, a Miles assay using VEGF was performed and
demonstrated a 65% reduction of acute vascular leakage following the
same oral Lodamin treatment for 5 days (Figure 7B).
Lodamin reduces ocular vascular permeability
In order to evaluate the effect of Lodamin on ocular vascular
leakage while excluding its direct angiogenesis inhibitory effects,
CNV lesions of the same stage were used to compare vessel
leakage in mice and in rats. Laser-induced CNV in rat retinas
were imaged by fluorescein angiography (n=6). Rats with
established CNV lesions (7 days post laser injury) were treated
with a single Lodamin treatment 3 h prior to quantifying leakage
(60 mg/kg). The lesions were graded using angiography and
showed a significant reduction of retinal vessel permeability
(Figure 7 C,D). A modified VEGF Miles assay was also performed
to evaluate Lodamin’s effect on ocular vessel permeability in mice
with an established CNV lesion. Similarly, when Lodamin (60mg/
kg, n=5) was administered once 3 h before Evans blue injection,
65% reduction in vessel leakage was obtained by this short-term
Lodamin treatment (Figure 7 E).
Polymeric micelles accumulate in CNV site
The biodistribution of fluorescent-labeled Lodamin in CNV
lesions was determined 3h post tail vein injection in C57Bl/6J
mice. A model fluorescent hydrophobic small molecule (6-
coumarin, MW=350 gr/mole, Sigma) was used to determine
differences between accumulations of the free molecule and its
encapsulated form. Compared with the free molecule, labeled
polymeric micelles were detected in greater extent in CNV sites
confirming passive targeting (Figure 7F, n=3). In a separate
experiment we used the same labeled micelles as a model to study
Lodamin’s distribution in the retina using retinal cross section in
mice. Micelles were injected intravitreally on the day of laser
Figure 4. Lodamin injected intravitreal suppresses CNV progression. (A) CNV lesions were induced by a diode pumped solid state laser
around the optic nerve through a slit lamp delivery system. Only lesions in which a subretinal bubble or focal serous detachment of the retina
developed were used for the experiments. Four burns were performed per eye while leaving a space around the optic disc. At the day of laser
induction intravitreal injection of Lodamin was performed. Size of CNV lesions after intravitreal injections of Lodamin: 100 mg Lodamin per eye
(12.5 mg TNP-470 equivalent) or 300 mg Lodamin per eye. Data is presented as mean pixel number 6 SEM (n=7–17, *P,0.05, U-test). (B)
Representative images of retinal flat-mounts stained with a lectin-FITC, Bars=10 mm.
doi:10.1371/journal.pone.0012515.g004
Ocular Neovascularization
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post injection (Figure 7G).
Methods
Mice (C57Bl/6J, 8 weeks old) were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). For rat studies, non
pigmented Lewis rats (8–10 weeks old, Charles River Laboratories)
were used. All protocols were approved by the Institutional
Animal Care and Use Committee at Children’s Hospital Boston
and were conducted in accordance with the Association for
Research in Vision and Ophthalmology’s Statement for the Use of
Animals in Ophthalmic and Vision Research. (Protocols no. A09-
10-1531 and A08-08-1208R CHB, 07-09-009, MEEI)
Cell culture
RPE cells were cultivated as has been previously described[11].
As determined by flow cytometry, the primary RPE cultures were
found to be more than 98% cytokeratin positive (Clone PCK-26,
Sigma). HMVECs, were purchased from Cambrex Bio Science Inc.
(Rockland, ME) and were maintained on collagen I coated plates
with endothelial cell growth medium containing 2% FBS (EGM-2;
Cambrex, Inc.) at 37uC with humidified 95% air / 5% CO2.
Preparation of Lodamin and florescent labeled micelles
Lodamin was prepared as previously described[10]. Briefly,
TNP-470 (D. Figg) was conjugated to a diblock co-polymer
mPEG-PLA using a two-step reaction. In the first step succinated
mPEG2000-PLA1000 with free carboxic acid end-groups (Ad-
vanced Polymers Materials) was reacted with ethylenediamine
(Sigma-Aldrich) by using ethyl(diethylaminopropyl) carbodiimide
(EDC) and a catalyst N-hydroxysuccinimide (NHS). In the second
step, the amine-containing polymer was mixed with TNP-470
(350 g), dissolved in DMSO and the solution was stirred for 4 h at
25uC. The polymeric micelles were formed by dialyzing the
DMSO solution of the conjugate against double distilled water
using a regenerated cellulose dialysis bag (MWCO 1000, Spectra/
Por Biotech Regenerated Cellulose, VWR). The micelles were
then lyophilized and stored at 220uC in a dry environment until
use. For fluorescent labeled Lodamin, a commonly used
hydrophobic marker 6-coumarin (Sigma-Aldrich) at 0.1% wt/wt
was added to the polymeric solution before the final dialysis step.
The doses of Lodamin as noted are presented as TNP-470
equivalent.
In vivo Matrigel angiogenesis assay
Briefly, C57BL/6J mice were inoculated subcutaneously with
growth factor-reduced Matrigel Matrix (BD Bioscience) mixed
with recombinant human VEGF (10 ng/ml) and bFGF (10 ng/
ml) (R&D Systems). Mice were treated with daily oral Lodamin for
7 day (15 mg/kg) or with the equivalent dose of vehicle (empty
micelles). After 7 days, Matrigel plugs were removed, embedded in
OCT medium (OCT, Tissue-Teck, USA) and immunohistochem-
istry was performed using Vectastain Elite ABC kit (Vector
Figure 5. Comparison of the effect of Lodamin or sFlk-1 on choroidal vessel regression. For CNV regression studies intravitreal injections
of Lodamin or sFlk-1, a recombinant mouse VEGF R2/KDR Flk-1 Fc Chimera, were performed on established CNV lesions at day 7 post laser induction.
After 14 days of laser induction (7 days post intravitreal injection of Lodamin or sFlk-1) fluorescent images of choroidal flat-mounts were captured and
CNV area (presented in mm
2) in choroidal flat mount was evaluated using Scion image software. (A) CNV size data of untreated mice bearing laser
induced CNV at day 7 and 14, compared to Lodamin or sFlk-1 treated mice 7 days after their injection. Data is presented as mean pixel number 6
SEM (n=15–27 spots, *P,0.05, U-test).
doi:10.1371/journal.pone.0012515.g005
Ocular Neovascularization
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12515Figure 6. Retinal ERG and protein analysis post Lodamin treatments. Effects of intravitreal Lodamin on retinal function. (A) Representative
full-field flash ERG responses from the eyes of mice 14 days after intra-ocular injection of vehicle (left) or 300mg /eye Lodamin (right). (B)
Representative responses to 8 Hz flicker (C) The 5
th to 95
th prediction limits for ERG parameters in vehicle treated rats are shown; the dashed line
represents the normal mean of all the paramters. Symbols are parameters values of individual Lodamin-treated mice, and represent the same mouse
in each column. Data are DLogNormal (eq. 3). Only the saturating amplitude of the rod photoresponse (RmP3) differed significantly after Lodamin. (D)
Effect of oral Lodamin treatment on protein levels of pro-angiogenic and pro-inflammatory factors. (D) Levels of MCP-1 and VEGF extracted from
whole eye tissues from naı ¨ve mice, mice treated with Lodamin (30mg/kg, oral every day for 7 d) or vehicle (same equivalent amount of mPEG-PLA
micelles). Data of ELISA assay are presented as a mean of pg/ml concentration 6 SD (n=6, * P,0.05, t-test). Bottom: ELISA quantification of secreted
MCP-1 from RPE to the medium post 24 h incubation with Lodamin at different doses (0.1–100 nM TNP-470 equivalent). (E) Western blot protein
analysis of samples of tissue lysis of retina or choroid of the different treatment groups: N=naı ¨ve mice, V=vehicle treated mice, L=Lodamin treated
mice. Factors detected are TNFa (26 kDa) (F) Zymogram showing MMP-2 and MMP-9 activity in ocular tissue following oral Lodamin treatment of
mice (30 mg/kg/day 7 days).
doi:10.1371/journal.pone.0012515.g006
Ocular Neovascularization
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12515Figure 7. Lodamin reduces vessel permeability in the modified Miles assay and in retinal angiography. (A) Left: quantification of
modified Miles assays performed in mice after induction of vessel permeability using MCP-1 (50 pg) and VEGF (50 ng); extracted dye contents were
quantified by measuring at 620 nm. Data are expressed as mean 6 SEM (n=10, *P,0.05, t-test). (B) Representative photos of mouse skin showing
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staining. Detection was carried out using a 3,3¢-diaminobenzidine
chromogen (DAB), which results in a positive brown staining.
Quantification of endothelial cells and macrophages in Matrigel
plugs was performed by FACS following enzymatic digestion of
Matrigel plugs as described elsewhere [12]. Immunostaining was
performed in the presence of rat anti-mouse F4/80-PE and CD45-
APC. Flow cytometry was performed using FACS Calibur and
CellQuest software (BD Biosciences, San Jose, CA, USA).
Endothelial cells were defined as CD31+CD452 and macrophag-
es were defined as F4/80
+ CD45
+ cells.
Corneal micropocket assay
The corneal micropocket angiogenesis assay was performed as
previously detailed[13]. Pellets containing 80 ng carrier-free
recombinant human bFGF (R&D Systems, Minneapolis, MN)
were implanted into micropockets created in the cornea of
anesthetized mice. Mice were treated daily with 15 mg/kg
Lodamin for 5 days, and then the vascular growth area was
measured using a slit lamp. Photos of mouse eyes were taken on
day 5 of treatment. The area of neovascularization was calculated
as vessel area by the product of vessel length measured from the
limbus and clock hours around the cornea, using the following
equation: Vessel area (mm
2)=(p6clock hours6vessel length
(mm)60.2 mm].
DTH reactions
DTH reactions were induced in the skin of 8-week-old C57Bl/
6J male mice as previously described [14]. Mice were sensitized by
topical application of 2% oxazolone solution in vehicle (acetone:
olive oil, 4:1 v/v) to the shaved abdomen (50 ml) and to each paw
(5 ml). After 5 days, right ears were challenged by topical
application of 10 ml of a 1% oxazolone solution, and the left ears
were treated with vehicle alone. On the same day mice were
treated with Lodamin (15 mg/kg orally) and ear thickness was
then measured daily (3 measurements per ear using a caliper) for
12 days. On day 12, 3 mice from each experimental group were
euthanized and their ears were removed, fixed in 10% formalin
and processed for H&E-stained paraffin sections and for
immunohistochemical staining. Specific antibodies for detecting
blood vessels (anti-CD31), macrophages (anti-F4/80) and mono-
cytes (anti-CD45) were used and avidin/biotin complex (ABC;
Vecstatin Elite. ABC kit; Vector Laboratories) followed by DAB
staining were performed obtaining a positive brown staining.
Induction of CNV and flat-mount preparation
Laser-induced CNV was generated by a previously described
technique with some modifications [15]. C57Bl/6J mice were
anesthetized with an intraperitoneal administration of avertin
(400 mg/kg). A mixture of 0.5% tropicamide and 0.5% phenyl-
ephrine hydrochloride (Mydrin P; Santen Pharmaceutical, Osaka,
Japan) was applied to both eyes to dilate the pupils. Lesions were
induced by a diode pumped solid state laser (0.1 s; spot size,
50 mm; power 150 mW) around the optic nerve through a slit
lamp delivery system using a Nidek photocoagulator (GYC2000,
Nidek, Osaka, Japan) while a hand-held cover slide was used as a
contact lens. Only lesions in which a subretinal bubble or focal
serous detachment of the retina developed were used for the
experiments. For this purpose, four burns were performed per eye
while leaving a space around the optic disc. Lodamin treatments
(oral or intravitreal) were started at the day of CNV induction (day
0) and the sizes of CNV lesions were determined after 7 or 14 days.
For regression studies the intravitreal injections of Lodamin or
sFlk-1 were performed at day 7 post laser induction. After 7 or 14
days of laser induction, mice were euthanized and their eyes were
removed and fixed in 4% paraformaldehyde for 60 min. The
cornea and lens were removed, and the entire retina was carefully
dissected from the eyecup. Radial cuts (average, eight) were made
from the edge of the eyecup to the equator, and then washed with
cold buffer (0.3% Tween 20) in PBS. Blood vessels were labeled
using a 1:200 dilution of isolectin IB4 conjugated with Alexa Fluor
488 (Invitrogen-Molecular Probes, Eugene, OR, USA) or lectin-
FITC (Vector Laboratories). The eyecup was flat-mounted in an
aqua-mount with the sclera facing down and the choroid facing
up. Fluorescent images of choroidal flat-mounts were captured
using a CCD camera (DC500, Leica, Switzerland). The CNV area
(presented in mm
2) in choroidal flat mount was evaluated using
Scion image software.
Analysis of cell population in retina by Flow cytometry
Single cell suspensions were prepared from C57BL/6J mouse
retinas with CNV lesions. In order to collect a sufficient number of
ocular-infiltrating cells for flow cytometry, 20 separate burns were
delivered similar to the panretinal photocoagulation procedure in
humans. The percent of macrophages in single-cell suspensions
originated from mouse retinas (days 3 and 7 post laser procedure)
was evaluated for Lodamin treated or untreated mice (3 days, oral,
30 mg/kg q.d). In the third day of treatment mice were
euthanized, the eyes were enucleated and the anterior segment
(cornea, iris, and lens) was removed. The posterior segment of the
eye including sclera, choroid, and retina was disrupted with
scissors and then incubated with 2.8 units/ml Liberase Blend-
zymes (Roche Indianapolis, IN, USA) at 37uC for 45 min.
Digested tissue was then filtered through a 40 mM cell strainer
and resuspended in FACS Buffer (PBS, 1%BSA, 5 mM EDTA/
0.05% sodium azide). Immunostaining was performed in the
presence of rat anti-mouse F4/80 PE and CD45-APC by
incubating the cells for 30 min on ice. Flow cytometry was
performed using FACS Calibur and CellQuest software (BD
Biosciences, San Jose, CA, USA). Macrophages were defined as
F4/80
+ CD45
+ cells. Preparations from two eyes were pooled in
order to obtain a sufficient number of viable cells for a flow
cytometric analysis in the above process. A total of four eyes (two
individual pools) were examined per group (5 mice per group).
diminished dye in mice treated with oral Lodamin 1 and 3 h before conducting the assay. MCP-1 induces vessel permeability in a dose dependent
manner, already at 10 pg/ml, MCP-1 induced significant vessel leak compared with PBS. (C) Fluorescein angiography of CNV lesions of rats treated
with Lodamin or vehicle. Fluorescein angiography was performed at day 7 after laser photocoagulation and Lodamin was administered 1 and 3 h
before performing the imaging. (D) The percentage of lesions graded as 0, I, IIA, defined as no leakage to moderate leakage, and IIB, considered
clinically relevant leakage, in vehicle-treated (n=6 eyes). A significant reduction of vessel leak was observed after an acute treatment of Lodamin.( E)
Lodamin reduces whole eye vessel permeability as determined by Evan’s blue extraction method. Mouse eyes treated with Lodamin (3 h before
conducting the assay) were 65% less than the control. Data are presented as mean 6 SD (n=5, *P,0.05, t-test). (F) Accumulation of 6-coumarin
labeled Lodamin injected i.v at the site of CNV lesion in mouse compared to an injection of free 6-coumarin. In red: blood vessels stained with
rhodamine concanavalin A, in green: 6-coumarin dye. Bar=20 mm. (G) Bioditribution of 6-coumarin labeled Lodamin (green) in mouse retina side
sections 1 day or 7 days post intravitreal injection. 10 mm Section were imaged by confocal microscopy using optical sections with 488-nm argon,
diode lasers. Bar=20 mm.
doi:10.1371/journal.pone.0012515.g007
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In order to determine whether MCP-1 affects vessel permeabil-
ity, a Miles assay was performed in C57Bl/6J mice. Briefly, shaved
mice were injected intravenously with 200 ml of 0.1% Evans blue
dye (Sigma). After 10 min, different concentrations of MCP-1
were injected intradermaly (i.d.) in designated spots on the mouse
back (5, 10, 50, 100, 250 pg/ml, 50ml per spot, 6 spots including
PBS). To quantify the extent of leakage, equally sized (8 mm
diameter) skin regions surrounding i.d. injection sites were
removed 30 min after injection and placed in 1 ml of formamide
at room temperature for 48 h allowing dye extraction. The optical
absorption of the samples was measured at 620 nm using 96 well
microplate reader Victor2 (PerkingElmer Life Siences, Boston,
MA, USA). In a separate experiment, we determined the effect of
Lodamin on vascular permeability in-vivo using standard Miles
assay. For these experiments C57Bl/6J mice were treated for 5
days with oral Lodamin (30 mg/kg/day). PBS (50 ml) and carrier
free VEGF (50 ng in 50 ml) or MCP-1 (R&D Systems, USA, 50 pg
in 50 ml) were injected i.d. in both left and right flanks as well as at
single or dual dorsal sites 10 min post Evans blue injection. The
extent of leakage was calculated by comparison with PBS-treated
controls.
Laser induced retinal vascular permeability
In order to specifically evaluate the effect of Lodamin on laser-
induced retinal leakage while excluding its anti-angiogenic activity,
CNV lesions of the same size (same day post laser injury) were
used to compare blood vessel permeability in mice and rats. Two
different assays were performed: modified Miles assay in mice and
angiography in rats. The modified Miles assay was performed
similarly to the standard procedure: in brief, CNV was induced by
laser beam (4 spots) as detailed above. Seven days post laser
procedure mice were treated with Lodamin (60 mg/kg) 3 h prior
to intra-orbital injection of Evan’s blue (100 ul, 0.1% in saline,
Sigma). After 10 min, mice were sacrificed, eyes were removed
and washed 3 times with PBS and Evan’s blue dye was extracted
using Formamide (0.5 ml/sample) for 48 h at 37uC. Two controls
were used: untreated CNV-bearing mice or naive mice.
Angiography was performed on rats using Fluorescein imaging.
In brief, 7 days post laser injury vascular leakage of CNV lesions
were assessed using fluorescein angiography (FA) as previously
described [16]. Briefly, FA was performed on anesthetized rats
from Lodamin treated or untreated groups, using a scanning laser
ophthalmoscope (SLO; HRA2; Heidelberg Engineering, Dossen-
heim, Germany). Fluorescein injections were administrated
intravenously (0.2 ml of 2% fluorescein; Akorn, Decatur,IL,
USA). The grading criterion was as follows: grade-0 lesions had
no hyperfluorescence, grade-I lesions exhibited hyperfluorescence
without leakage, grade-IIA lesions exhibited hyperfluorescence in
the early or midtransit images and late leakage. Grade-IIB lesions
showed bright hyperfluorescence in the transit images and late
leakage beyond the treated areas, Grade-IIB lesions were defined
as clinically significant.
Biodistribution
In order to evaluate the accumulation of Lodamin in its micelle
structure at the CNV lesion site, a comparison between free or
encapsulated fluorescent marker was performed. Lodamin labeled
with 6-coumarin (1 mg/kg) was injected into the retro-orbital
plexus of mice while an equivalent dose of free 6-coumarin (in
ethanol) was injected as control. After 3 h cornea and lens were
removed, and the entire retina was carefully dissected from the
eyecup. Radial cuts were made from the edge of the eyecup to the
equator, and then washed with PBS. Blood vessels were labeled
using a 1:50 dilution of rhodamine concanavalin A (RL-1002,
Vector Laboratories, Burlingame, CA, USA). The eyecup was flat-
mounted in an aqua-mount with the sclera facing down and the
choroid facing up. Fluorescent images of choroidal flat-mounts
were captured using OpenLab software version 2.2.5 (Improvision
Inc.) with standardized illumination and contrast. In order to
evaluate ocular distribution and drug stability we performed a
separate experiment in which 6-coumarin labeled Lodamin was
injected intravitreally into mice (100 mg/eye). After 1 day or 7 days
post laser induction and drug injection, eyes were removed and a
serial of side sections (10 mm) were taken to detect the CNV lesion
site. The distribution of labeled Lodamin was detected by confocal
1 and 7 days post injection in histological side sections of mouse
eyes. Sections were imaged by confocal microscopy using optical
sections with 488-nm argon, diode lasers. Bar=20 mm.
Antibodies and materials
We used the following specific antibodies for western blot: anti
mouse TNFa (abcam, # ab6671), anti- NFkB p65 (SantaCruz
Biotechnology, # sc-109), HRP-anti-actin (Sigma, #A3854). For
FACS analysis we used PE-F4/80, APC-CD45 and PE-CD31
purchased from BD bioscience. For immunohistochemistry we
used anti-CD31, anti-CD45, anti-F4/80 antibodies from BD
Bioscience. Recombinant mouse VEGF R2/KDR/Flk-1 Fc
Chimera (sFlk-1) was purchase from R&D Systems. General
reagent was obtained from Sigma-Aldrich unless noted otherwise.
Zymography
Gelatin zymography was used to examine levels of MMP-9 and
MMP-2 in the samples. Equal amounts of protein (50 ug) were
mixed with sample buffer and resolved via electrophoresis using
10% Ready Gel Zymogram Precast Gels with gelatin (BioRad
Laboratories, Hercules, CA). After electrophoresis, gels were
soaked in Zymogram Renaturing Buffer (BioRad Laboratories,
Hercules, CA) for 30 minutes with gentle agitation at room
temperature. The gels were then rinsed and incubated overnight at
37uC in Zymogram Developing Buffer (BioRad Laboratories,
Hercules, CA). Later, the gels were stained for 15–30 min in 0.5%
Coomassie Blue R-250 in acetic acid, isopropyl alcohol, and water
(1:3:6), distained for 1 h in acetic acid, ethanol, and water (1:3:6),
and then photographed. The enzyme activity was detected as clear
bands on uniform blue stained background. Recombinant mouse
MMP-9 and MMP-2 (R&D Systems, Minneapolis, MN) were used
as positive control.
Protein analysis
To measure protein level in ocular tissue, an equal number of
mouse retinas and choroids isolated from the different treatment
groups were lysed in RIPA buffer (n=5). CNV bearing mice were
burned with high energy laser in 20 spots to enhance the immune
reaction. The total protein level in the tissue samples was
determined using microBCA kit (Pierce, Rockford IL ,USA) and
an equal amount of 50 mg total protein was mixed with66 sample
buffer (2% SDS, 60 mM Tris, HCl pH 6.8, 0.02% DTT). The
samples were then separated in 4–20% SDS-PAGE and
transferred to a Polyvinylidene Fluoride (PVDF) membrane
(BioRad). Reaction of Horseradish peroxidase (HRP)-conjugated
secondary antibodies against specific primary antibodies followed
by ECL development (Amersham), and autoradiography (Kodak
films) were performed. Similar protocol was used for cell-lyses
protein analysis. To measure murine VEGF and MCP-1 levels in
tissues, standard ELISA kits were used following manufacturer
instruction (R&D systems).
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Dark-adapted full-field ERGs were obtained as previously
described [17]. By fitting the Hood and Birch formulation [18] of
the Lamb and Puch model [19,20] of phototransduction to the a-
wave, we obtained the photoreceptor’s kinetics (Srod) and
saturated amplitude (RmP3). From the response vs. intensity
relationship of P2, the putatively-pure postreceptor response
derived from the b-wave we determined bipolar sensitivity (log
kP2) and saturated amplitude (RmP2). The oscillatory potentials
(OPs) obtained after passing P2 through a 5th-order Butterworth
filter (bandpass 50–250 Hz) were evaluated in the frequency
domain [21] to estimate maximal OP energy (Em). Finally, the
retinal response to light-adapted 8 Hz flicker was measured (R8).
Prior to ERG testing, mice were adapted to dark overnight. All
preparations were made under dim, red illumination as previously
described [17] for the rat, except that the electrode was fitted to
the eye of the mouse. We delivered stimuli and collected responses
using an Espion e
2 with ColorDome Ganzfeld stimulator
(Diagnosys LLC, Lowell, MA). The timing and intensity of the
stimuli were fully under computer control and thus did not differ
between subjects. Signals were amplified in the frequency range of
0.3–1,000 Hz and sampled at a minimum of 2,000 Hz. Body
temperature was maintained with a heating pad. Flash intensity is
reported in nominal units.
Photoreceptor function were evaluated by ensemble fitting the
Hood and Birch model[18]of the activation of phototransduction
to the leading edge of the ERG a-waves elicited by bright, xenon
arc flashes which saturated the rod photocurrent. The model takes
flash intensity (i) and elapsed time (t) as its inputs, such that P3(i,
t)=(12exp(2KNSrodNiN(t2td)
2))NRmP3 for td,t,10 ms, (eq. 1) where
Srod summarizes the kinetics of the series of processes initiated by
the photoisomerization of rhodopsin and resulting in closure of the
channels in the plasma membrane of the photoreceptor, td is a
brief delay, and RmP3 is the saturated amplitude of the
photoreceptor response (mV). Srod is related to the amplification
constant (A) of Lamb and Pugh[19,20] and RmP3 is proportional to
the magnitude of the dark current[22].To evaluate postreceptor
retinal function, a series of ‘green’ LED flashes were presented,
from one eliciting a small (,20 mV) b-wave to one saturating the
rod bipolar cells’ response, and derived the putatively pure
postreceptor response, P2, was derived by digitally subtracting the
derived photoreceptor response, P3 (eq. 1), from each intact ERG.
We obtained objective estimates of P2 amplitude by fitting of an
inverted gamma function to the derived responses[23]. To
determine the maximal amplitude of the rod bipolar cell response
(RmP2), we fit the Michaelis-Menton equation, f(i)=aNi
b/(i
b+c
b) eq. 2
to the response vs. intensity relationship of P2, where f(i) is the
amplitude (mV) of the bipolar cell response (P2) to a stimulus of i
intensity (RP2), a (mV) is defined as RmP2, and c is the is the flash
intensity that elicits a P2 response with half-maximal amplitude,
defined as kP2; the exponent, b, was fixed at unity. Log kP2 was
taken as a measure of post-receptor sensitivity.
To demonstrate the electroretinographic oscillatory potentials
(OPs), we passed the derived P2 responses through a digital, 5
th-
order Butterworth filter (MATLAB; The MathWorks, Natick,
MA) with band-pass 50 to 250 Hz; the resulting OPs were
evaluated in the frequency domain as previously described[21]. In
brief, we subjected the first 256 samples (128 ms) of each record to
discreet Fourier transform (radix-2 FFT algorithm; MATLAB) to
produce a power spectrum. Then, to characterize the OPs, we fit
the data by a Gaussian, the integral of which we took as
proportional to OP energy (joules). We obtained an estimate of
maximal OP energy, Em, by fitting eq. 2 such that f(i) is the energy
of the OPs in the response to a stimulus of i intensity, a is defined
as Em, and, c is the flash intensity which elicits OPs with half-
maximal energy; b was free to vary.
A cone-mediated retinal response was elicited by presenting
8 Hz ‘green’ square-wave flicker in the presence of an ‘amber’
background that suppressed the saturating, dark adapted a-wave
by .80%. We measured the trough-to-peak amplitude of the
flicker response, R8. We expressed ERG data as DLogNormal:
DLogNormal x ðÞ ~log x ðÞ {
P n
mouse~1
log vehicle mouse ðÞ
n
eq.3where
x an individual observation and n is the number of vehicle-treated
mice (10). By expressing the data in log values, changes in observations
of fixed proportion, either up or down, become linear, consistent with
a constant fraction for physiologically meaningful changes in
parameter values [17].
Analysis of cell population in retina by flow cytometry
Single cell suspensions were prepared from C57BL/6J mouse
retinas with CNV lesions. In order to collect a sufficient number of
ocular-infiltrating cells for flow cytometry, 20 separate burns were
delivered similar to the panretinal photocoagulation procedure in
humans. The quantity of macrophages in single-cell suspensions
(originated from mouse retinas from days 3 and 7 post laser
procedure) was evaluated for Lodamin treated (oral, 30 mg/kg q.d
for 3 days), vehicle or untreated mice. In the third day of treatment
mice were euthanized and retinas analyzed.
Statistical Analysis
For CNV and retinal permeability studies a Mann–Whitney U-
test was used using PrisM software. For the other studies an
unpaired, two-tailed Student’s t-test was used when comparing
between the different groups. The significance level (a) for all tests
was p,0.05. For ERG studies the statistical analysis is detailed in
the methods.
Discussion
Significant progress has been made towards the elucidation of
the pathophysiology of angiogenesis and the role of antiangiogenic
therapies in the treatment of pathological neovascularization [24].
This has accelerated the development of antiangiogenic therapies
for neovascular AMD and drug development for other retinal
pathologies [24]. To date inhibition of angiogenesis, both directly
and indirectly, is one of the leading therapeutic approaches in
neovascular AMD.
However, ocular drug-delivery faces many challenges for new
drugs, particularly for lipophilic compounds that cannot be
introduced directly in aqueous solutions. Many small-molecule
angiogenic inhibitors, such as TNP-470, have poor water solubility
necessitating the development of unique formulations to facilitate
their use. For these drugs, particulate formulations can offer
improved ocular drug delivery since they are usually more stable
than other colloidal systems. Lodamin comprises many of the
requirements for advanced ocular delivery: it can be introduced
into an aqueous solution, is nontoxic, biocompatible, biodegrad-
able, and has slow-release properties[10]. This is the first report of
Lodamin as treatment for retinal neovascular disorders.
Lodamin was found to be significantly effective in suppressing
laser induced CNV in mice, both by oral daily administration and
by single intravitreal injection, where up to 75% inhibition was
obtained using only a single injection. In fact, its activity was able
to promote regression of the CNV lesions by 45% post a single
intravitreal injection. This ability of Lodamin was particularly
important considering the fact that VEGF inhibitors can reduce
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we confirmed that a potent VEGF inhibitor, sFlk-1, inhibited
CNV growth but could not regress the vessels once established.
The stronger activity of Lodamin can be explained by its broad
mechanism of action combined with its high stability and slow
release properties. In addition, these characteristics reduce the
need for repeated, frequent injections required in order to achieve
therapeutic outcomes, as currently exist with VEGF blockers.
Our data demonstrated Lodamin’s suppressive effects on
vascular permeability and inflammation, in addition to its direct
effect on angiogenesis. This can be partly explained by our
findings that the treatment led to a substantial reduction of
secreted MCP-1 protein level in RPE cells and in CNV lesions in
mice. RPE cells are responsible for generating and maintaining the
extracellular and photoreceptor matrices, as well as the integrity of
Bruch’s membrane. Impaired function of these cells can cause
lipid and protein accumulation in the vicinity of Bruch’s
membrane and result in formation of drusen that is commonly
found in AMD patients [25]. RPE cells secrete chemoattractants
and various pro-inflammatory cytokines such as interleukin-8 (IL-
8), MCP-1 and TNFa. MCP-1, a small cytokine of the C-C
chemokine family, is a potent chemoattractant for neutrophils and
macrophages which stimulatates angiogenesis and vascular leak,
further contributing to AMD progression [26–27]. Elevated MCP-
1 levels have been found in the vitreous of patients with retinal
neovascularization [26,28]. Moreover, MCP-1 has been associated
with other systemic inflammatory and autoimmune diseases such
as diabetes and proliferative vitreoretinal disorders [29,30]. In
support of these observations, our in vivo data showed that
Lodamin suppressed MCP-1 production at the CNV site and this
was accompanied with a reduction of infiltrating macrophages in
the retina.
Interestingly, we found that Lodmain could antagonize MCP-1
induced vascular leak in a dose dependant manner as potently as
when VEGF was used as the inducer of vascular permeability.
These results can explain the significant reduction that was found
in retinal edema following angiography or Evan’s blue extraction,
and also the diminished tissue edema and spongiosis found in the
DTH reaction. It should be noted that the effect of the drug on
retinal edema was very rapid, as only a single oral pretreatment
3 h prior to angiography was sufficient to substantially reduce of
vessel permeability.
The reduction of MCP-1 levels by Lodamin was found to be
associated with a diminution of the transcription factor nuclear
factor k-B (NFkB) in the choroids of Lodamin treated mice. NFkB
regulates the production of MCP-1 (which is stimulated by TNF-a
and IL-6) and is known to be a key payer in the immune response,
cancer, inflammatory and autoimmune diseases. [31]. Lodamin
suppressed other pro-angiogenic and pro-inflammatory factors
including VEGF, TNFa and matrix metalloproteinases (MMPs) at
the CNV site, effectively preventing the progression of ocular
neovascularization.
The gold standard treatment of neovascular, or wet, AMD is
primarily based on VEGF targeting, despite the critical role of
other cytokines and growth factors such as MCP-1, TNF a and
basic fibroblast growth factor (bFGF) in AMD pathology [4].
Because Lodamin can target broader molecular pathways, we
expect it will improve therapeutic outcomes compared to VEGF
blockers. Furthermore, the specific structure of Lodamin, a
polymeric nanomicelle, enhances its accumulation in CNV lesions
compared to the injection of free small molecule (as seen in
Figure 7F) suggesting ideal biodistribution via systemic adminis-
tration. This effect may be due to the Enhanced Permeability and
Retention effect (EPR)[32] caused by the leaky vasculature in
neovascular sites. Importantly, despite the broad spectrum activity
of Lodamin, it was well tolerated and showed minimal toxicity in
the retina as indicated by histological analysis and ERG. Further
studies are required to determine the effects following chronic use.
Lastly, the slow release properties of Lodamin suggested that the
frequency of treatments can be reduced. This is particularly
important in the case of intravitreal injection, which is more
problematic for patients, requires clinician expertise, and is
associated with some risks.
Taken together, we maintain that broad spectrum antiangio-
genic drugs such as Lodamin are important candidates for
therapeutic treatment of ocular neovascular diseases in humans
and can bring a major change in the approach to AMD
treatment.
Supporting Information
Figure S1 Lodamin inhibits angiogenesis and inflammatory
response in Matrigel plug angiogenesis assay and DTH reaction.
(A) Upper panel: representative Matrigel plugs exposed under
mouse skin (bar=1 cm). Vehicle treated mice presented bloody
plugs surrounded by massive blood vessels, compared to Lodamin
treated mice which had poor vasculature. bar=100mm. Lower
panel: FACS dot plots of endothelial cells (CD31+/CD45, marked
in red squares) or macrophages (CD45+F4/80+, marked in red
squares) from single cell suspension originated from Matrigel
plugs. (B) Immunohistological analysis of mice ears post DTH
reaction: staining of macrophages using F4/80 marker. Control
ears exhibited an excessive inflammation. Bar=50 mm. No
obvious difference was found in macrophage distribution however,
the total number of macrophages present in control mice was
elevated due to greater amount of tissue, associated with increased
swelling.
Found at: doi:10.1371/journal.pone.0012515.s001 (9.63 MB
TIF)
Figure S2 Evaluation of retinal toxicity post intravitreal
injection of Lodamin (A)Retinal electroradiography post Lodamin
intravitreal injection. The a-waves in response to the eight
brightest flashes are replotted at increased gain. The black
portions are fitted with the Hood and Birch model of the
activation of phototransduction (eq. 1; colored lines). (B) Fits of eq.
2 to the response vs. intensity relationship of P2. Drop lines
indicate the intensity that elicits a flash with half-maximum
amplitude. (C) Histological cross sections of retinal tissues. Retinal
tissues taken 14 days post intravitreal injection of Lodamin
(300 mg/eye) were compared to naı ¨ve mouse retinas. Represen-
tative images are shown (Bars=50 mm). No apparent retinal tissue
changes were detected, both eyes presented normal structures of
(1) choroid (2) photoreceptors (3) outer nuclear layer (4)outer
plexiform layer (5) inner nuclear layer (6) inner plexiform layer and
(7) ganglion cell layer. The total retinal thickness remained
unchanged.
Found at: doi:10.1371/journal.pone.0012515.s002 (5.11 MB TIF)
Figure S3 Induction of vessel permeability by MCP-1 demon-
strated in Miles assay. Representative photos of mouse skin
showing dose response MCP-1-induced vessel permeability. Graph
represent the quantification of Miles assays performed in mice
after induction of vessel permeability using MCP-1 (5, 10, 50, 100,
250 pg); extracted dye contents were quantified by measuring at
620 nm. Data are expressed as mean 6 SEM (n=10, *P,0.05,
t-test).
Found at: doi:10.1371/journal.pone.0012515.s003 (2.05 MB
TIF)
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